Roth Capital Maintains Buy On Discovery Laboratories Following 3Q14 Update
In a research report sent to investors today, Roth Capital analyst Scott Henry maintained a Buy rating on Discovery Laboratories (NASDAQ:DSCO) with a $5 price target, which represents a potential upside of 191% from where the stock is currently trading. The report follows the company’s third-quarter results
Henry observed, “DSCO reported a 3Q14 EPS loss that was within the range of expectations. We viewed the quarter as fundamentally on the weaker side due to a slower than targeted near-term Surfaxin ramp (another downward revision for our targets) and slight delays (again) to the Aerosurf 2a clinical data. Still, we believe that there are encouraging signs for both programs and that expectations have already been reset lower (again).”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Scott Henry has a total average return of 12.6% and a 47.5% success rate. Henry has a 8.9% average return when recommending DSCO, and is ranked #350 out of 3363 analysts.